{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:02:27Z","timestamp":1790107347260,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2004,8,19]],"date-time":"2004-08-19T00:00:00Z","timestamp":1092873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1007\/s00213-004-1991-7","type":"journal-article","created":{"date-parts":[[2004,8,18]],"date-time":"2004-08-18T10:27:47Z","timestamp":1092824867000},"page":"167-173","source":"Crossref","is-referenced-by-count":75,"title":["Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients"],"prefix":"10.1007","volume":"178","author":[{"given":"Roel","family":"Verheul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lehert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Geerlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten W. J.","family":"Koeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,8,19]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s002130000607","volume":"154","author":"N Ait-Daoud","year":"2001","unstructured":"Ait-Daoud N, Johnson BA, Prihoda TJ et al. (2001) Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 154:23?27","journal-title":"Psychopharmacology"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/01621459.1957.10501379","volume":"52","author":"TW Anderson","year":"1957","unstructured":"Anderson TW (1957) Maximum likelihood estimates for a multivariate normal distribution when some observations are missing. J Am Statist Assoc 52:200?203","journal-title":"J Am Statist Assoc"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.1998.tb04295.x","volume":"22","author":"J Besson","year":"1998","unstructured":"Besson J, Aeby F, Kasas A et al. (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22:573?579","journal-title":"Alcohol Clin Exp Res"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","volume":"35","author":"J Chick","year":"2000","unstructured":"Chick J, Howlett H, Morgan MY et al. (2000) United Kingdom Multicenter Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35:176?188","journal-title":"Alcohol Alcohol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/10543409808835246","volume":"8","author":"CC Choi","year":"1998","unstructured":"Choi CC (1998) Sample size in clinical trials with dichotomous endpoints, use of covariables. J Biopharm Stat 8:367?375","journal-title":"J Biopharm Stat"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1126\/science.2882604","volume":"236","author":"CR Cloninger","year":"1987","unstructured":"Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236:410?416","journal-title":"Science"},{"key":"CR7","first-page":"100","volume-title":"Design and analysis of clinical experiments","author":"J Fleiss","year":"1985","unstructured":"Fleiss J (1985) Design and analysis of clinical experiments. Wiley, New York, pp 100?101"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000259166","volume":"3","author":"PJ Geerlings","year":"1997","unstructured":"Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 3:129?137","journal-title":"Eur Addict Res"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0011-393X(05)80480-1","volume":"52","author":"G Gerra","year":"1992","unstructured":"Gerra G, Caccavari R, Delsignore R et al. (1992) Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Curr Ther Res 52:291?295","journal-title":"Curr Ther Res"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0165-1781(97)00147-9","volume":"77","author":"G Gerra","year":"1998","unstructured":"Gerra G, Ferri M, Zaimovic A et al. (1998) GABAergic function in detoxified heroin addicts: relationship to anxiety disorders. Psychiatry Res 77:89?96","journal-title":"Psychiatry Res"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/alcalc\/36.5.413","volume":"36","author":"A Gual","year":"2001","unstructured":"Gual A, Lehert Ph (2001) Acamprosate during and after acute alcohol withdrawal: a double blind placebo controlled study in Spain. Alcohol Alcohol 36:413?418","journal-title":"Alcohol Alcohol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","volume":"284","author":"BA Johnson","year":"2000","unstructured":"Johnson BA, Roache JD, Javors MA et al. (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284:963?971","journal-title":"JAMA"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","volume":"60","author":"F Kiefer","year":"2003","unstructured":"Kiefer F, Jahn H, Tarnaske T et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92?99","journal-title":"Arch Gen Psychiatry"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1037\/0033-2909.92.2.513","volume":"92","author":"P Koele","year":"1982","unstructured":"Koele P (1982) Calculating power in analysis of variance. Psychol Bull 92:513?516","journal-title":"Psychol Bull"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1530-0277.2001.tb02356.x","volume":"25","author":"HR Kranzler","year":"2001","unstructured":"Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335?1341","journal-title":"Alcohol Clin Exp Res"},{"key":"CR16","first-page":"182","volume":"50","author":"D Ladewig","year":"1993","unstructured":"Ladewig D, Knecht T, Lehert P et al. (1993) Acamprosate: a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 50:182?188","journal-title":"Ther Umsch"},{"key":"CR17","first-page":"67","volume":"59","author":"Ph Lehert","year":"1994","unstructured":"Lehert Ph (1994) Guidelines on evaluation of treatment of alcohol dependence. Alcoholism 59:67","journal-title":"Alcoholism"},{"issue":"Suppl","key":"CR18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/oxfordjournals.alcalc.a008221","volume":"31","author":"OM Lesch","year":"1996","unstructured":"Lesch OM, Walter H (1996) Subtypes of alcoholism and their role in therapy. Alcohol Alcohol 31(Suppl):63?67","journal-title":"Alcohol Alcohol"},{"key":"CR19","volume-title":"Statistical analysis with missing data","author":"RJA Little","year":"1987","unstructured":"Little RJA, Rubin DB (1987) Statistical analysis with missing data. Wiley, New York"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1360-0443.1995.tb01088.x","volume":"90","author":"J Littleton","year":"1995","unstructured":"Littleton J (1995) Acamprosate in alcohol dependence: how does it work? Addiction 90:1179?1188","journal-title":"Addiction"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-80193-8_2","volume-title":"Acamprosate in relapse prevention of alcoholism","author":"J Littleton","year":"1996","unstructured":"Littleton J, al Qatari M, Little H (1996) The neurobiology of craving: potential mechanisms for acamprosate. In: Soyka M (ed) Acamprosate in relapse prevention of alcoholism. Springer, Berlin Heidelberg New York, pp 27?46"},{"issue":"Suppl 20","key":"CR22","first-page":"42","volume":"62","author":"BJ Mason","year":"2001","unstructured":"Mason BJ (2001) Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 62(Suppl 20):42?48","journal-title":"J Clin Psychiatry"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/105504901750532148","volume":"10","author":"JR Monterosso","year":"2001","unstructured":"Monterosso JR, Flannery BA, Pettinati H et al. (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10:258?268","journal-title":"Am J Addict"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","volume":"28","author":"DW Oslin","year":"2003","unstructured":"Oslin DW, Berrettini W, Kranzler HR et al. (2003) A functional polymorphism of the ?-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546?1552","journal-title":"Neuropsychopharmacology"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1192\/bjp.171.1.73","volume":"171","author":"I Pelc","year":"1997","unstructured":"Pelc I, Verbanck P, Le Bon O et al. (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171:73?77","journal-title":"Br J Psychiatry"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1360-0443.1997.tb02873.x","volume":"92","author":"F Poldrugo","year":"1997","unstructured":"Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92:1537?1546","journal-title":"Addiction"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0165-6147(92)90065-E","volume":"13","author":"HH Samson","year":"1992","unstructured":"Samson HH, Harris RA (1992) The neurobiology of alcohol abuse. Trends Pharmacol Sci 13:206?211","journal-title":"Trends Pharmacol Sci"},{"key":"CR28","first-page":"551","volume":"30","author":"H Sass","year":"1995","unstructured":"Sass H (1995) Results from a pooled analysis of 11 European trials comparing acamprosate and placebo in the treatment of alcohol dependence [abstract]. Alcohol Alcohol 30:551","journal-title":"Alcohol Alcohol"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archpsyc.1996.01830080023006","volume":"53","author":"H Sass","year":"1996","unstructured":"Sass H, Soyka M, Mann K et al. (1996) Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673?680","journal-title":"Arch Gen Psychiatry"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1037\/0022-006X.64.4.669","volume":"64","author":"MA Schuckit","year":"1996","unstructured":"Schuckit MA (1996) Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 64:669?676","journal-title":"J Consult Clin Psychol"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0165-6147(97)89800-8","volume":"18","author":"R Spanagel","year":"1997","unstructured":"Spanagel R, Zieglg\u00e4nsberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18:54?59","journal-title":"Trends Pharmacol Sci"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/alcalc\/35.2.202","volume":"35","author":"E Tempesta","year":"2000","unstructured":"Tempesta E, Janiri L, Bignamini A et al. (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence. A placebo-controlled study. Alcohol Alcohol 35:202?209","journal-title":"Alcohol Alcohol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1176\/ajp.155.6.726","volume":"155","author":"GE Tsai","year":"1998","unstructured":"Tsai GE, Ragan P, Chang R et al. (1998) Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 155:726?732","journal-title":"Am J Psychiatry"},{"key":"CR34","first-page":"16","volume":"2","author":"W Brink Van den","year":"2003","unstructured":"Van den Brink W (2003) The role of psychosocial interventions in the pharmacological treatment of alcohol dependence. Drugs Ther Perspect 2:16?21","journal-title":"Drugs Ther Perspect"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/alcalc\/34.2.197","volume":"34","author":"R Verheul","year":"1999","unstructured":"Verheul R, van den Brink W, Geerlings PJ (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34:197?222","journal-title":"Alcohol Alcohol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(96)91682-7","volume":"347","author":"AB Whitworth","year":"1996","unstructured":"Whitworth AB, Fischer F, Lesch OM et al. (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347:1438?1442","journal-title":"Lancet"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2165\/00003495-199753060-00008","volume":"53","author":"MI Wilde","year":"1997","unstructured":"Wilde MI, Wagstaff AJ (1997) Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53:1038?1053","journal-title":"Drugs"},{"key":"CR38","volume-title":"Statistical principles in experimental design","author":"BJ Winer","year":"1989","unstructured":"Winer BJ (1989) Statistical principles in experimental design, 3rd edn. McGraw Hill, New York","edition":"3"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-004-1991-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-004-1991-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-004-1991-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T08:55:42Z","timestamp":1734512142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-004-1991-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,19]]},"references-count":38,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["1991"],"URL":"https:\/\/doi.org\/10.1007\/s00213-004-1991-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,19]]}}}